Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...
CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, ...
Or could those jumping on the morning shed trend actually sabotage their beauty goals? We spoke to dermatologists and hair ...
The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...
The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...
On today’s CT BUZZ, Host Natasha Lubczenko sat down with Dr. Zach Korwin, owner of Sleep Stratford, to discuss an innovative ...
My wife, who bore the brunt of my transformation into a grumpy badger, was the first to suggest I get a sleep study. She’d ...
CPAP therapy, the traditional standard for obstructive sleep apnea (OSA), is universally despised by patients, resulting in abysmally low compliance rates. Recent studies show it also fails to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback